Acquired BTK and PLCG2 mutations by patients
Patient ID . | Treatment arm . | Acquired BTK mutation at PD: coding DNA description (CCF, %) . | Acquired BTK mutation at PD: protein description . | Acquired PLCG2 mutation at PD: coding DNA description (CCF, %) . | Acquired PLCG2 mutation at PD: protein description . | Duration of treatment (mo) . |
---|---|---|---|---|---|---|
1 | Ibrutinib | c.1442G>C (1.79) | p.C481S | Not detected | Not detected | 30.8 |
2 | Ibrutinib | c.1442G>C (13.71) | p.C481S | Not detected | Not detected | 34.5 |
3 | Ibrutinib | c.1442G>C (1.88) | p.C481S | c.2535A>C (1.28) | p.L845F | 11.8 |
c.127G>C (1.09) | p.D43H | |||||
4 | Ibrutinib | Not detected | Not detected | c.3422T>A (6.76) | p.M1141K | 18.8 |
5 | Zanubrutinib | c.1442G>C (24.56) | p.C481S | Not detected | Not detected | 34.2 |
6 | Zanubrutinib | c.1283C>A (37.03) | p.A428D | Not detected | Not detected | 28.0 |
c.1442G>C (5.62) | p.C481S | |||||
c.1441T>A (2.95) | p.C481S | |||||
7 | Zanubrutinib | c.1442G>C (18.89) | p.C481S | Not detected | Not detected | 29.7 |
c.1583T>G (9.58) | p.L528W | |||||
c.1441T>A (4.99) | p.C481S | |||||
c.1442G>A (2.13) | p.C481Y | |||||
c.1442G>T (1.98) | p.C481F | |||||
c.1441T>C (1.18) | p.C481R | |||||
8 | Zanubrutinib | c.1583T>G (17.6) | p.L528W | Not detected | Not detected | 33.8 |
9 | Zanubrutinib | c.1442G>C (77.72) | p.C481S | Not detected | Not detected | 18.4 |
c.1441T>C (2.40) | p.C481R | |||||
c.1441T>A (0.47) | p.C481S |
Patient ID . | Treatment arm . | Acquired BTK mutation at PD: coding DNA description (CCF, %) . | Acquired BTK mutation at PD: protein description . | Acquired PLCG2 mutation at PD: coding DNA description (CCF, %) . | Acquired PLCG2 mutation at PD: protein description . | Duration of treatment (mo) . |
---|---|---|---|---|---|---|
1 | Ibrutinib | c.1442G>C (1.79) | p.C481S | Not detected | Not detected | 30.8 |
2 | Ibrutinib | c.1442G>C (13.71) | p.C481S | Not detected | Not detected | 34.5 |
3 | Ibrutinib | c.1442G>C (1.88) | p.C481S | c.2535A>C (1.28) | p.L845F | 11.8 |
c.127G>C (1.09) | p.D43H | |||||
4 | Ibrutinib | Not detected | Not detected | c.3422T>A (6.76) | p.M1141K | 18.8 |
5 | Zanubrutinib | c.1442G>C (24.56) | p.C481S | Not detected | Not detected | 34.2 |
6 | Zanubrutinib | c.1283C>A (37.03) | p.A428D | Not detected | Not detected | 28.0 |
c.1442G>C (5.62) | p.C481S | |||||
c.1441T>A (2.95) | p.C481S | |||||
7 | Zanubrutinib | c.1442G>C (18.89) | p.C481S | Not detected | Not detected | 29.7 |
c.1583T>G (9.58) | p.L528W | |||||
c.1441T>A (4.99) | p.C481S | |||||
c.1442G>A (2.13) | p.C481Y | |||||
c.1442G>T (1.98) | p.C481F | |||||
c.1441T>C (1.18) | p.C481R | |||||
8 | Zanubrutinib | c.1583T>G (17.6) | p.L528W | Not detected | Not detected | 33.8 |
9 | Zanubrutinib | c.1442G>C (77.72) | p.C481S | Not detected | Not detected | 18.4 |
c.1441T>C (2.40) | p.C481R | |||||
c.1441T>A (0.47) | p.C481S |